ROSEMONT, Ill.--(BUSINESS WIRE)--Proteintech, the benchmark in antibodies, today announced the winners of the 2018 AACR Travel Grant awards. Ramya Ravindran at the University of Michigan and Samaresh Sau at Wayne State University have each been awarded $1,000 each to cover expenses to attend the 2018 American Association for Cancer Research (AACR) annual meeting, being held April 14 - 18 in Chicago, IL.
Ravindran studies diffuse intrinsic pontine glioma (DIPG). DIPG is a fatal pediatric brainstem tumor with 100% fatality. These tumors are often treated on the assumption that they are molecularly similar to adult high-grade gliomas; however, they are distinct. Ravindran and her colleagues have generated a genetically engineered mouse model of DIPG which represents a novel platform to study the molecular pathways underlying disease pathogenesis. An understanding of the functions of mutations that lead up to the disease can help to develop novel therapies for DIPG.
“Excited to be presenting at the AACR 2018 Conference. Thankful to Proteintech for their support in making this possible,” said Ravindran. She will be presenting her research in the 8am – 12pm poster session on April 18.
Sau’s work is focused on improving immunotherapy treatment. Programmed death ligand -1 (PD-L1) checkpoint inhibitors such as atezolizumab have been revolutionizing cancer treatment. However, the potential of these drugs has not been fully realized. To improve the stromal penetration of checkpoint inhibitors to tumors, Sau and colleagues have chemically linked a chemotherapeutic agent to atezolizumab for immune-chemo combination therapy. Their current data suggest that this approach may significantly improve the potency of checkpoint inhibitors for multiple cancer types.
“I am delighted to network and develop cancer-killing smart drugs,” said Sau, who will be presenting this work in the 8am – 12pm poster session on April 17.
“AACR is one of the scientific highlights of the year,” says William Olds, scientific officer at Proteintech, “AACR is a wonderful catalyst for careers and discoveries.”
About Proteintech Group
Proteintech is an antibody manufacturer selling directly to scientists and only selling its own products to maintain the highest level of quality control leading to superior reproducibility and lot consistency. With over 2/3 of the human genome completed, we have a catalog of over 12,000 antibodies against 12,000 targets covering almost complete spectrum of research areas. To view tens of thousands of publications and in-house validation images in WB, IHC, IF, FC, IP, CHIP, Knock-down siRNA using our antibodies and to learn more about Proteintech and their mission to deliver products directly from their bench to the researcher’s bench, please visit www.ptglab.com